S-Nitrosylation in Neurodegeneration

S-Nitrosylation in Neurodegeneration

Overview

S-nitrosylation is a reversible post-translational modification (PTM) in which a nitric oxide (NO) group is covalently attached to the thiol side chain of cysteine residues, forming an S-nitrosothiol (SNO). This modification serves as a critical signaling mechanism in the nervous system, regulating protein function, neuronal communication, and cellular homeostasis. However, dysregulated S-nitrosylation has emerged as a key pathological mechanism in neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) [1]. [@nitric]

S-Nitrosylation in Neurodegeneration

Overview

S-nitrosylation is a reversible post-translational modification (PTM) in which a nitric oxide (NO) group is covalently attached to the thiol side chain of cysteine residues, forming an S-nitrosothiol (SNO). This modification serves as a critical signaling mechanism in the nervous system, regulating protein function, neuronal communication, and cellular homeostasis. However, dysregulated S-nitrosylation has emerged as a key pathological mechanism in neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) [1]. [@nitric]

Unlike chronic inflammation and oxidative stress, which represent broad cellular stress responses, S-nitrosylation represents a precise molecular pathway through which nitric oxide orchestrates both physiological signaling and pathological cascades. The modification is mediated by nitric oxide synthases (NOS) — neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS) — and is reversed by denitrosylases including thioredoxin (Trx) and S-nitrosoglutathione reductase (GSNOR). [@snitrosylation]

Molecular Mechanisms of S-Nitrosylation

Chemistry and Enzymology

S-nitrosylation occurs through multiple biochemical pathways: [@snitrosylationa]

Enzymatic S-nitrosylation: The three NOS isoforms catalyze the production of NO, which can directly react with cysteine thiols to form S-nitrosocysteine: [@snitrosylated]

• nNOS (NOS1): Calcium/calmodulin-dependent, localized to synapses and perisynaptic regions
• eNOS (NOS3): Primarily endothelial but expressed in some neuronal populations
• iNOS (NOS2): Inducible under inflammatory conditions, produces high-output NO

Protein-SNO + Cysteine → Protein + Protein-Cys-SNO

This reaction is catalyzed by proteins including thioredoxin and protein disulfide isomerase (PDI). [@snitrosylationc]

Denitrosylation: The reverse reaction is equally important physiologically: [@role]

• Thioredoxin (Trx) system: Trx reduces S-nitrosylated cysteines using NADPH
• GSNOR (S-nitrosoglutathione reductase): Metabolizes GSNO to GSSG and NH₃
• Cysteinase: Copper-containing denitrosylase

Target Cysteine Motifs

Not all cysteines are equally susceptible to S-nitrosylation. Susceptibility depends on: [@thioredoxin]

• Acid-base motif: Presence of adjacent acidic (Asp, Glu) and basic (Lys, Arg) residues
• Hydrophobic environment: Cysteines in hydrophobic pockets are more readily modified
• Local pKa: Lower pKa thiols are more reactive
• NO concentration: Physiological vs. pathological NO levels determine modification extent

Key Proteins Affected in Neurodegeneration

Parkin and Mitophagy

S-nitrosylation of Parkin represents one of the best-characterized pathological S-nitrosylation events. Parkin is an E3 ubiquitin ligase critical for mitophagy — the selective [autophagy](/entities/autophagy) of damaged mitochondria [2].

Normal function: Parkin, activated by PINK1 phosphorylation, ubiquitinates mitochondrial outer membrane proteins, targeting damaged mitochondria for degradation.

S-nitrosylation pathology: In PD and related disorders, excessive nNOS-derived NO S-nitrosylates Parkin at Cys³⁶⁵, inhibiting its E3 ligase activity [2]. This impairs mitophagy, leading to accumulation of dysfunctional mitochondria, increased oxidative stress, and dopaminergic neuron death.

The S-nitrosylated Parkin is functionally inactive, unable to ubiquitinate mitochondrial proteins, creating a vicious cycle where impaired mitophagy leads to further oxidative/nitrosative stress.

GAPDH and Energy Metabolism

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a key glycolytic enzyme that is also subject to pathological S-nitrosylation.

S-nitrosylation at Cys¹⁵⁰: In [neurons](/entities/neurons) exposed to NO donors or under oxidative stress, GAPDH is S-nitrosylated at Cys¹⁵⁰ [3]. This modification:

• Inhibits glycolytic activity, reducing ATP production
• Promotes GAPDH nuclear translocation
• Triggers pro-apoptotic signaling through binding to SIAH1

Protein Disulfide Isomerase (PDI)

PDI is an ER chaperone that catalyzes disulfide bond formation and reduction. S-nitrosylation of PDI in neurodegenerative diseases impairs its protective function [4].

ER stress amplification: When PDI is S-nitrosylated, it loses its chaperone and isomerase activity, leading to accumulation of misfolded proteins in the ER lumen [4]. This triggers the [unfolded protein response](/entities/unfolded-protein-response) (UPR), and when chronic, leads to ER stress-induced [apoptosis](/entities/apoptosis).

In ALS, PDI S-nitrosylation contributes to the accumulation of misfolded SOD1 and [TDP-43](/mechanisms/tdp-43-proteinopathy) aggregates [4].

Caspase-3

Caspase-3, the executioner caspase of apoptosis, can be regulated by S-nitrosylation.

Protection against apoptosis: At low NO concentrations, S-nitrosylation of caspase-3 at Cys¹⁷⁸ protects the enzyme from activation, providing a cytoprotective effect.

Pathological implications: However, in chronic neurodegenerative conditions, the balance shifts — prolonged nitrosative stress can ultimately lead to caspase activation and apoptosis through mechanisms including mitochondrial permeabilization and cytochrome c release.

TDP-43 and Protein Aggregation

In ALS and frontotemporal dementia (FTD), TDP-43 forms characteristic cytoplasmic inclusions. S-nitrosylation may influence TDP-43 aggregation propensity [5].

Modulation of aggregation: S-nitrosylation of specific cysteine residues in TDP-43 may alter its conformational stability and aggregation kinetics [5]. The relationship is complex, with both protective and pathological effects reported depending on the specific cysteine and cellular context.

S-Nitrosylation in Specific Neurodegenerative Diseases

Alzheimer's Disease

In AD, multiple pathways converge to produce excessive nitrosative stress:

Amyloid-β interaction: [Aβ](/proteins/amyloid-beta) peptides stimulate nNOS and iNOS activity, increasing NO production in the vicinity of synapses [1]. This leads to:

• Synaptic protein S-nitrosylation (including PSD-95, synaptophysin)
• Impairment of [long-term potentiation](/mechanisms/long-term-potentiation) (LTP)
• [Tau](/proteins/tau) pathology amplification through kinase/phosphatase S-nitrosylation

• [GSK-3β](/entities/gsk3-beta): S-nitrosylation at Cys⁷⁶⁷ promotes tau hyperphosphorylation
• [PP2A](/entities/pp2a): S-nitrosylation inhibits the major tau phosphatase
• BACE1: Paradoxically, S-nitrosylation may increase [β-secretase](/entities/bace1) activity, enhancing Aβ production

Parkinson's Disease

PD is particularly associated with S-nitrosylation due to the vulnerability of dopaminergic neurons to nitrosative stress [6]:

Dopamine metabolism: Dopamine oxidation produces [reactive oxygen species](/entities/reactive-oxygen-species) and can stimulate NOS activity. Combined with mitochondrial complex I deficiency, this creates a permissive environment for S-nitrosylation [6].

Parkin S-nitrosylation: As described above, this represents a critical pathogenic mechanism, impairing mitophagy [2].

[α-Synuclein](/proteins/alpha-synuclein): S-nitrosylation of α-synuclein at Cys⁵⁰ may influence its aggregation propensity, though this remains an area of active investigation [5].

DJ-1: The Parkin co-substrate DJ-1 (PARK7), which loses its protective function in early-onset PD, can be S-nitrosylated. This modification may regulate its oxidative stress-sensing function.

Amyotrophic Lateral Sclerosis

ALS presents a particularly compelling case for S-nitrosylation involvement [7]:

SOD1 mutations: While most ALS-causing SOD1 mutations are not directly related to nitrosylation, the presence of mutant SOD1 leads to increased oxidative and nitrosative stress [7].

TDP-43 pathology: S-nitrosylation may influence TDP-43 mislocalization and aggregation [5].

Motor neuron vulnerability: Motor neurons appear particularly susceptible to nitrosative stress, possibly due to their high metabolic demands and excitability [7].

iNOS upregulation: In ALS spinal cord, iNOS is upregulated in activated [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes), producing high local NO concentrations [7].

Huntington's Disease

In HD, mutant [huntingtin](/proteins/huntingtin) (mHtt) protein promotes nitrosative stress through multiple mechanisms:

nNOS activation: mHtt can bind to and activate nNOS, increasing NO production.

Mitochondrial dysfunction: S-nitrosylation of mitochondrial proteins contributes to the bioenergetic deficit characteristic of HD.

Transcription regulation: S-nitrosylation of transcription factors including [NF-κB](/entities/nf-kb) and HIF-1α alters gene expression patterns relevant to neuronal survival.

Therapeutic Implications

NOS Inhibitors

Non-selective NOS inhibitors have been tested in neurodegenerative models but face challenges:

• L-NAME: Improves outcomes in some PD models but lacks brain penetration
• Selective nNOS inhibitors: More targeted but may impair beneficial NO signaling

Denitrosylation Enhancement

Enhancing endogenous denitrosylation pathways represents a promising strategy:

Thioredoxin (Trx) system: Overexpression of Trx or Trx reductase protects against nitrosative stress in models [8].

GSNOR inhibition: Paradoxically, GSNOR inhibition may increase S-nitrosylation in the short term but can trigger adaptive antioxidant responses.

S-Nitrosothiol-Based Therapies

S-nitrosoglutathione (GSNO) and related compounds can:

• Provide controlled NO release
• Promote beneficial S-nitrosylation of target proteins
• Support mitochondrial function

Antioxidant Approaches

Given the close relationship between oxidative and nitrosative stress:

• NAC (N-acetylcysteine): Provides cysteine for glutathione synthesis
• CoQ10: Supports mitochondrial electron transport, reducing secondary oxidative stress
• Mitochondrial antioxidants: Targeted delivery of antioxidants to mitochondria

Cross-Talk with Other Post-Translational Modifications

S-nitrosylation does not occur in isolation — it interacts with other PTMs:

Phosphorylation

• cAMP-dependent protein kinase (PKA): Can phosphorylate nNOS, regulating its activity
• GSK-3β: Reciprocal regulation with S-nitrosylation affects tau pathology

Ubiquitination

• Competition for cysteine: Some cysteines can be either S-nitrosylated or ubiquitinated
• Parkin E3 ligase: S-nitrosylation directly inhibits ubiquitination activity [2]

Acetylation

• Histone acetylation: NO can regulate histone acetyltransferases and deacetylases
• Metabolic enzymes: Dual regulation by S-nitrosylation and acetylation coordinates metabolic responses

SUMOylation

• Competition or cooperation: Some proteins can be modified by SUMO or SNO at overlapping sites

Measurement and Detection

Detecting S-nitrosylated proteins in tissue and biological samples remains methodologically challenging:

Chemical Methods

• Biotin switch assay: Classic method using ascorbate to reduce SNO to thiol, then biotinylation
• SNO-RAC: Variant with improved sensitivity
• Mass spectrometry: Identifies specific S-nitrosylated cysteines

Imaging

• S-nitrosysteine immunostaining: Antibody-based detection
• Fluorescent probes: DaF-Family dyes for live-cell imaging

Challenges

• Transient nature: S-nitrosylation is reversible, complicating detection
• Artifact prevention: Avoiding artefactual S-nitrosylation during sample handling
• Quantification: Accurate measurement of modification stoichiometry

Future Directions

Key questions remain:

• Temporal dynamics: When during disease progression does S-nitrosylation become pathological?
• Cell-type specificity: Which cell types (neurons, glia, endothelium) contribute most to pathological S-nitrosylation?
• Therapeutic targeting: Can we develop selective denitrosylating agents or NOS modulators with brain penetration?
• Biomarker potential: Are S-nitrosylated proteins detectable in CSF or blood as disease biomarkers?

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research Updates (2024-2026)

• [JW et al. 2025: Melatonin confers saline-alkali tolerance in tomato by alleviating nit](https://pubmed.ncbi.nlm.nih.gov/39928568/)
• [CK et al. 2024: Redox regulation, protein S-nitrosylation, and synapse loss in Alzheim](https://pubmed.ncbi.nlm.nih.gov/39515322/)
• [KK et al. 2024: MDM2 induces pro-inflammatory and glycolytic responses in M1 macrophag](https://pubmed.ncbi.nlm.nih.gov/39366973/)
• [T et al. 2024: Protein S-nitrosylation under abiotic stress: Role and mechanism.](https://pubmed.ncbi.nlm.nih.gov/38184883/)
• [Z et al. 2024: Systematic analysis of the global characteristics and reciprocal effec](https://pubmed.ncbi.nlm.nih.gov/39218121/)

References